October 26, 2023
Novocure Reports Third Quarter 2023 Financial Results
Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023 ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023. Novocure is a global oncology company working to extend survival in some of… Read More
learn more
October 15, 2023
Novocure Announces Presence at European Society for Medical Oncology (ESMO) Congress 2023
Highlights include a new analysis showing that Tumor Treating Fields therapy, when added to standard systemic therapies, did not adversely affect patients’ quality of life in the phase 3 LUNAR clinical trial. ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced its participation in the European Society for… Read More
learn more
October 12, 2023
Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical… Read More
learn more
October 2, 2023
Novocure to Report Third Quarter 2023 Financial Results
ROOT, Switzerland–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and… Read More
learn more
